Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.

About Numiera Therapeutics Numiera is a preclinical-stage pharmaceutical company focused on developing small-molecule ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Romania's Sibiu County Emergency Clinical Hospital will receive a robotic system to prepare cytostatic drugs needed by cancer ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...